Global InformationAmatuximab information
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | mesothelin |
| Clinical data | |
| Other names | MORAb-009 |
| ATC code |
|
| Identifiers | |
| CAS Number |
|
| ChemSpider |
|
| UNII |
|
| Chemical and physical data | |
| Formula | C6394H9870N1694O2024S46 |
| Molar mass | 144331.89 g·mol−1 |
  (what is this?) (verify) | |
Amatuximab (development code MORAb-009) is a chimeric monoclonal antibody designed for the treatment of cancer.[1] It was developed by Morphotek, Inc.
Amatuximab is a monoclonal antibody that binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing.[2][3]
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Amatuximab" (PDF). American Medical Association.
- ^ Baas HI, Hassan R, Nowak AK, Rice D (2018). "Chapter 53: Malignant mesothelioma.". In Pass HI, Ball D, Scagliotti GV (eds.). IASLC Thoracic Oncology (2nd ed.). Elsevier. pp. 536–549.e4. doi:10.1016/B978-0-323-52357-8.00053-6. ISBN 978-0-323-52357-8.
- ^ Baldo P, Cecco S (2017). "Amatuximab and novel agents targeting mesothelin for solid tumors". OncoTargets and Therapy. 10: 5337–5353. doi:10.2147/OTT.S145105. PMC 5687483. PMID 29184420.